Lawsuit Filed Against Savara Inc. for Alleged Securities Law Infractions - Affected Investors Advised to Consult The Gross Law Firm Prior to November 7, 2025 Regarding Legal Options - SVRA
The Gross Law Firm, a nationally recognised class action law firm dedicated to protecting investors, has issued a notice to shareholders of Savara Inc. (NASDAQ: SVRA). The notice pertains to the company, traded on NASDAQ under the ticker symbol SVRA, and relates to shareholders who purchased shares of SVRA during the class period from March 4, 2024, to May 23, 2025.
The notice stems from allegations that Savara Inc.'s treatment for pulmonary alveolar proteinosis, MOLBREEVI BLA, lacked sufficient information regarding its chemistry, manufacturing, and controls. The complaint further suggests that the FDA was unlikely to approve MOLBREEVI BLA in its current form. Additionally, it is alleged that the delay in MOLBREEVI's regulatory approval increased the likelihood that the Company would need to raise additional capital.
Shareholders who wish to be part of the class action are encouraged to register before the deadline of November 7, 2025. Appointment as lead plaintiff is not required to partake in any recovery. Shareholders who register will be enrolled in a portfolio monitoring software for case updates.
If you are a Savara Inc. shareholder and believe you have suffered losses due to false and/or misleading statements or the omission of material information by the company leading to artificial inflation of the company's stock, you are invited to contact the Gross Law Firm. The firm's mission is to ensure companies adhere to responsible business practices and engage in good corporate citizenship.
For more information or to discuss the possibility of lead plaintiff appointment, please visit the Gross Law Firm's website at https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=167828&from=3 or contact the firm directly at 15 West 38th Street, 12th floor, New York, NY, 10018, email [email protected], or phone (646) 453-8903. There is no cost or obligation for shareholders to participate in the case.
